



NDA 20-911/S-005

3M Pharmaceuticals
3M Center
Building 270-3A-08
St. Paul, MN 55144-1000

Attention: Amy Fowler
Senior Regulatory Associate

Dear Ms. Fowler:

Please refer to your supplemental new drug application dated June 29, 2001, received July 10, 2001, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol.

We acknowledge receipt of your submissions dated August 7, 2001, and February 20, April 5, and 30, and May 6, and 7, 2002.

This supplemental new drug application provides for the use of QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol for maintenance treatment of asthma in children 5 through 11 years of age.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling proposed (package insert submitted May 7, 2002).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-911/S-005." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have not fulfilled the requirements of 21 CFR 314.55 (or 601.27) for pediatric patients from birth to < 60 months of age. We are deferring submission of your pediatric studies for patients \geq 6 months and < 60 months of age until December 31, 2003. A waiver is justified for pediatric patients < 6 months of age.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Ms. Ladan Jafari, Regulatory Project Manager, at (301) 827-1084.

Sincerely,

{See appended electronic signature page}

Robert J. Meyer, M.D.
Director
Division of Pulmonary and Allergy Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Meyer

5/10/02 01:47:37 PM